MRI-guided stereotactic body radiotherapy (SBRT) for prostate cancer was found to be more effective than CT-guided SBRT in a study presented at the American Society for Radiation Oncology (ASTRO) 2024 Annual Meeting by Dr. Amar Kishan. The MIRAGE trial, which enrolled 156 patients, showed that MRI guidance led to reduced toxicity, improved quality of life, and better prostate cancer treatment outcomes. The study demonstrated that MRI-guided SBRT was associated with lower rates of genitourinary and gastrointestinal toxicity, as well as better patient-reported quality of life measures. Further long-term follow-up and larger studies are needed to confirm the lasting benefits of this approach.
Source link
MRI-Guided SBRT for Prostate Cancer?
